EVER SINCE I was a graduate student, I remember getting immense pleasure out of seeing a well-controlled, cleanly performed experiment, whether it was mine or not. For those of us interested in how cells function, the use of cell lines and primary cell cultures permits tightly controlled experimental conditions, enabling inquiries about the mechanisms involved in physiological processes of virtually every cell type. There is just one problem, which is recognized by all who study cells in vitro and to which we all have comfortably accommodated: mammalian cells were not meant to live on plastic dishes or on synthetic membranes. Although in vitro model systems have borne a rich harvest of knowledge about cellular physiology, the cells are studied in an abnormal environment lacking such typical extracellular influences as the appropriate substratum and other cell types, as well as immune, neural, hormonal, and many other signals that can affect everyday cell function. One approach to the problem, long used, is to improve the in vitro environment to make it more lifelike. This has certainly been beneficial. Another approach, which is relatively new, is to try to study individual cell types in living animals. The latter, although technically more challenging, is ultimately more valuable.
Thus it was with considerable pleasure that I read the study of Sramkova et al. (13) . They are hardly the first to study cellular physiology in living animals. For more than 10 years, investigators have employed intravital two-photon microscopy to observe physiological processes in situ in such disparate tissues as brain (8, 15) , kidney (4, 12) , lymphoid tissue (14, 16) , microvessels (11), skin (10) , and bone (7). Sramkova et al. not only observed intravital cellular function in "another" tissue, they also conducted thoughtful, well-controlled experiments in which they showed how to manipulate, as well as monitor, function in highly differentiated epithelial cells within living animals. As such, they are part of a small group of investigators who have begun to define for the biological community a new standard for our understanding of how mammalian cells work.
The actual experiments performed by Sramkova et al. (13) are fairly simple: they consist of minimally invasive and carefully controlled direct gene transfer into a readily targeted tissue (submandibular gland) with use of a common reporter gene to identify transfected cells. Furthermore, they employ different, often-used experimental maneuvers with this easily accessed tissue to transfect different types of cells from their apical surfaces. In addition, their studies employ rats vs. mice, although Sramkova et al. are not the first to perform intravital microscopy in rats (4, 15) . I think the ability to manipulate and study specific cells in a living rat tissue is notable, not only because of the 10-fold animal size difference, but also because mice tend to be more experimentally malleable. I suspect that, before too long, it will be possible to employ the general experimental strategy and comparable manipulations used by Sramkova et al. in a larger animal model, e.g., rabbits (12) , moving us closer to application of the gained knowledge in human biology.
Although Sramkova et al. (13) have not solved any fundamental biological problem, their studies suggest that cell physiologists can use many of the same genetic manipulations and experimental maneuvers commonly employed with in vitro cell models to answer major questions in a living, breathing animal. The possibilities are limited only by one's imagination, and in their discussion, Sramkova et al. give readers a taste of what can be done by suggesting several such lines of important physiological research, i.e., membrane trafficking, cytoskeletal dynamics, and signal transduction. Accordingly, I also suspect that it will not be very long until we learn if many of the mechanistic truths of cellular physiology that we "know" from past cell culture studies actually exist in vivo in salivary and other exocrine glands. Furthermore, given the numerous and frequent advances in clinical medicine with accessing various tissues endoscopically, by in vivo, real-time imaging and by microsurgical techniques, intravital microscopic studies of distinct cell populations of numerous nonexocrine tissues seem to be fair game for imaginative investigators.
As someone who has worked for more than 15 years on clinical, as well as biological, applications of in vivo gene transfer, I was somewhat surprised by the comment of Sramkova et al. (13) that the efficiency of cell transfection achieved in vivo was too low to be used for gene therapy. Although it is a small part of their article, to me, this comment is the other side of a very important coin. Their statement may be generally true, although obviously the therapeutic value of any gene transfer depends on the specific disorder targeted and whether the level of transgenic protein expression attained is sufficient for a therapeutic effect. This has not been studied for any disease model under the experimental conditions defined by Sramkova et al., but it is, for me, a quite secondary issue. From my perspective, in the context of gene therapy, two other issues are much more relevant. First, the gene therapy community is working hard to develop novel vectors, both viral and nonviral, that will result in greatly enhanced and longer-lived cell transduction or transfection, respectively, in vivo. Enhanced transgenic protein expression obviously means that lower vector doses can be used, which is important for patient safety, as well as for applications to study cell physiology. Although they do not specifically study individual salivary cell physiology, Sramkova et al. are attentive to it when considering the results of their various experimental manipulations. Indeed, whether manipulations such as plasmid transfection or viral vector transduction lead to significant stress on target cells should be a real concern for any gene transfer application, physiological or clinical.
Nevertheless, efficient and safe gene transfer is not only based on the quality or dose of the gene transfer vector. Equally important is a detailed understanding of the physiological traits operative in the targeted cell that could affect the extent, stability, and applicability of the gene transfer. Thus the second key issue for me is that, for gene therapy to be successful in any tissue, it must be based on a sound understanding of that tissue's physiology. I hope that investigators in the gene therapy community see the study of Sramkova et al. (13) and recognize the value of using intravital imaging to better understand the physiology operative in their target cell of choice. Such studies will also lead to improvements in the efficiency of gene transfer and lessen the required doses of vectors, viral and nonviral, to which patients are exposed.
For those interested in protein secretion from salivary (and other exocrine) glands, I think the importance of the study of Sramkova et al. (13) cannot be understated. Exocrine glands are essential secretory tissues, yet our mechanistic understanding of how protein is secreted from them remains fairly elementary, in large part because there have been essentially no useful in vitro cell models in which the regulated secretory pathway is stably maintained. This situation exists, despite the significant and substantive efforts of a few laboratories (3, 5) . With apologies to all for my parochialism, a good example of the need to better understand secretory cell physiology to enhance gene therapy is one close to my heart: the use of salivary glands as a target depot for making transgenic secretory proteins for therapeutic use either in the upper gastrointestinal tract via saliva (an obvious use) or into the bloodstream for systemic applications (2) . Although the latter may sound a bit strange to many readers, given the classical exocrine function of salivary glands, it has been recognized for many years that salivary glands can also secrete proteins into the bloodstream, i.e., in an endocrine direction, in the absence of pathology (6, 9) .
After numerous in vivo, animal model gene transfer experiments, a key issue emerged that limits any clinical application of salivary gland gene transfer for the production of therapeutic secretory proteins. Independent of vector efficacy and the levels of transgenic secretory protein produced or its biological activity, we cannot predict the sorting pathway to be followed by the transgenic secretory protein in a highly differentiated, exquisitely polarized cell such as a salivary acinar or duct cell. Solution of this problem requires careful molecular and cellular physiological research. For example, it has been shown that human parathyroid hormone, a regulated pathway secretory protein, is secreted primarily into saliva from the rat submandibular gland, but primarily into serum from the mouse submandibular gland (1) . Similarly, transgenic human erythropoietin, a constitutive pathway secretory protein, is primarily secreted into serum from macaque parotid glands, but overwhelmingly into saliva from the parotid glands of miniature pigs (17) .
Without boring the reader with additional examples, suffice it to say that, given such an array of diverse observations, it is difficult to consider clinical applications of secretory protein gene transfer to salivary glands without knowing which molecules control the pathway to be followed by a transgenic secretory protein in a salivary gland, human or otherwise. It seems reasonable to suggest that by following the general approach described by Sramkova et al. (13) , i.e., the step-wise use of gene additions or ablations in specific cells in living animals, it should be possible to manipulate the known molecules involved in secretory and membrane protein sorting and elucidate this very real physiological conundrum and doubtless many others. 
